Repurposing Tazemetostat for the Treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 Patient
Latest Information Update: 23 Nov 2021
At a glance
- Drugs Tazemetostat (Primary)
- Indications Adult respiratory distress syndrome; COVID-19 respiratory infection; Cytokine release syndrome
- Focus Therapeutic Use
- Acronyms IST
- 17 Nov 2021 Planned initiation date changed from 22 Sep 2021 to 1 Jan 2022.
- 17 Nov 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.(Due to FDA recommendation cited safety issues )
- 26 Aug 2021 New trial record